Florbetaben F-18 (Neuraceq®): A Comprehensive Monograph on a Key Diagnostic Agent for Amyloid Pathology

Section 1: Compound Profile and Chemical Characteristics

This section establishes the fundamental identity of Florbetaben F-18, serving as a foundational reference by detailing its nomenclature, classification, and key physicochemical properties. These characteristics are critical for understanding its biological behavior, mechanism of action, and application in positron emission tomography (PET).

1.1 Nomenclature and Identification

Florbetaben F-18 is a small molecule radiopharmaceutical recognized by a variety of names and identifiers across scientific, regulatory, and commercial domains. Its consistent identification is crucial for research, clinical practice, and regulatory oversight.

The internationally recognized generic name is Florbetaben (¹⁸F).[1] It is marketed exclusively under the brand name Neuraceq®.[3] In scientific literature and during its development phase, it was also referred to by the development codes BAY94-9172 and AV-1.[1]

From a chemical standpoint, its structure is precisely defined by the International Union of Pure and Applied Chemistry (IUPAC) systematic name: 4-[(E)-2-[2-[2-(2-($^{18}$F)fluoranylethoxy)ethoxy]ethoxy]phenyl]ethenyl]-N-methylaniline.[2] This name describes every component of the molecule, including the radioactive fluorine-18 isotope.

For database and regulatory tracking, Florbetaben F-18 is assigned several unique identifiers. The Chemical Abstracts Service (CAS) has assigned it the number 902143-01-5.[3] In the DrugBank database, it is cataloged under the accession number DB09148.[1] Other key identifiers include its Unique Ingredient Identifier (UNII) TLA7312TOI and its Chemical Entities of Biological Interest (ChEBI) ID, CHEBI:79033.[1] These identifiers ensure unambiguous reference to the specific active substance in global databases and regulatory filings.